<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00357331</url>
  </required_header>
  <id_info>
    <org_study_id>0604008486</org_study_id>
    <nct_id>NCT00357331</nct_id>
  </id_info>
  <brief_title>The Effects of Potassium Citrate on Bone Metabolism</brief_title>
  <official_title>A Randomized Placebo Controlled Double Blind Investigation of the Effects of Potassium Citrate on Bone Metabolism in Postmenopausal Osteopenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Skeletal buffering of chronic acid loads may contribute to a significant amount of bone loss&#xD;
      over time. Evidence from a few small short-term studies suggests that basic compounds, namely&#xD;
      potassium citrate and potassium bicarbonate may reduce bone loss and improve bone density.&#xD;
&#xD;
      The purpose of this study is to evaluate the effects of potassium citrate on bone metabolism.&#xD;
      We hypothesize that administration of potassium citrate to postmenopausal women with&#xD;
      osteopenia will reduce bone resorption and improve bone mineral density.&#xD;
&#xD;
      Postmenopausal women with osteopenia (T score between -1.0 and -2.5) and no history of&#xD;
      fracture will be randomized to either daily potassium citrate or placebo for one year.&#xD;
      Primary outcomes will be markers of bone turnover, which will be measured over 12 months.&#xD;
      Secondary outcomes will be bone mineral density, compliance, and adverse events.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants were recruited from a single academic center. Subjects underwent screening at&#xD;
      the Clinical Translational Science Center (CTSC) at Weill Cornell Medical College (WCMC).&#xD;
      Study visits occurred at the CTSC where investigators administered and monitored&#xD;
      questionnaires, compliance, adverse events, and endpoint measurements. Subjects were assigned&#xD;
      an anonymous study number at the beginning of the trial, which was used to track the&#xD;
      participant's data throughout the study. The protocol was approved by the Institutional&#xD;
      Review Board (IRB) and the procedures followed were in accordance with the ethical standards&#xD;
      of the IRB and the CTSC. All patients provided informed consent.&#xD;
&#xD;
      Treatment Groups Participants were assigned to either the treatment or placebo group using a&#xD;
      randomization schema generated by the statistician. The randomization method was blocked&#xD;
      randomization with a blocking factor of 4. The blocked randomization was not stratified by&#xD;
      any other factors. The study was conducted in a double blind manner. The study medication,&#xD;
      K-citrate, or placebo, was dispensed through the New York Presbyterian Hospital (NYPH)&#xD;
      pharmacy. Bottles in the pharmacy were sequentially numbered and the number was linked to the&#xD;
      blocked randomization scheme. Only the statistician and the pharmacist knew the meaning of&#xD;
      the numbered codes and only the statistician knew the blocking assignment. Blocked&#xD;
      randomization with balanced randomization of each block and blocks of the same size was&#xD;
      performed by the RANDOM procedure within the WinPepi Version 11.1.&#xD;
&#xD;
      Investigators who administered questionnaires and assessed compliance, adverse effects or&#xD;
      endpoint information were blind to group assignment. Only study investigators were able to&#xD;
      enroll participants in the study and assign them to treatment arms. Those assigned to the&#xD;
      treatment group received the study drug (40 mEq daily K Citrate: two 10 mEq tablets twice&#xD;
      daily); those assigned to the control group received inert tablets of the same quantity. All&#xD;
      participants received daily supplementation with Citracal (630 mg calcium citrate and 400 IU&#xD;
      vitamin D3 per two caplets). All supplements and medications were provided by Mission&#xD;
      Pharmacal/Bayer Pharmaceuticals in Boerne, Texas. Subjects discontinued their prior&#xD;
      supplements at the time of entry to the study and were advised to adhere to the standardized&#xD;
      supplementation regimen outlined by the protocol.&#xD;
&#xD;
      Measurements and Outcomes Subjects were evaluated at baseline, 1, 3, 6, and 12 months. The&#xD;
      following outcomes were measured: change in bone turnover markers including u-NTX, BSAP, OC&#xD;
      and P1NP; changes in 24 hour urinary concentrations of citrate, sulfate, and calcium; and&#xD;
      changes in BMD measured from baseline to 12 months. Adverse events and compliance were&#xD;
      measured at each visit over the study duration. Adverse events pertained to medication side&#xD;
      effects, including, but not limited to, gastrointestinal complaints, nausea, diarrhea, and&#xD;
      stomach pain, as well as the development of hyperkalemia or metabolic acidosis. If any of the&#xD;
      following occurred, potassium exceeded 5.2 mmol/L; bicarbonate level exceeded 32 mmol/L;&#xD;
      creatinine increased by more than 30% or rose above 2.0 ng/dL; or GFR was &lt; 60, study&#xD;
      medications were stopped until the parameter normalized, at which point the medication was&#xD;
      resumed at half dose: Compliance was assessed by remaining pill count; good compliance was&#xD;
      defined at ≤ 20% of pills remaining, or ≤ 18 pills remaining for each 3-month dose&#xD;
      allocation.&#xD;
&#xD;
      Baseline measurements included dietary assessment (block food frequency questionnaire) and&#xD;
      blood pressure. Laboratory evaluation was performed at the General Core Laboratory at WCMC&#xD;
      and included a basic metabolic panel, calcium, albumin and thyroid stimulating hormone (TSH).&#xD;
      25-OH and 1,25(OH)2 Vitamin D were measured by radioimmunoassay (Immunodiagnostic Systems,&#xD;
      Scottsdale, Arizona). The interassay coefficient of variation (CV) was &lt;8.2% and &lt;13%,&#xD;
      respectively. Intact parathyroid hormone (i-PTH) was measured by immunoradiometric assay&#xD;
      (Scantibodies Laboratories, Santee, California; CV &lt;6.4%). Markers of bone turnover included&#xD;
      osteocalcin (OC: quantitative immunoradiometric assay, DiaSorin, Stillwater, Minnesota; CV&#xD;
      &lt;9.5%) , bone specific alkaline phosphatase (BSAP: solid phase monoclonal antibody&#xD;
      immunoenzymetric assay, Immunodiagnostics Systems, Scottsdale, Arizona; CV&lt;6.4%), procollagen&#xD;
      type 1 amino-terminal propeptide (P1NP: quantitative radioimmunoassay, Orion Diagnostica,&#xD;
      Espoo, Finland; CV&lt;9.8%), urinary N-telopeptide (U-NTX: quantitative enzyme-linked&#xD;
      immunosorbent assay kit, Wampole Laboratories INC Princeton, New Jersey; CV&lt;5.0%). All&#xD;
      specimens were collected as fasting morning samples. The urinary-NTX was a second morning&#xD;
      void. The specimens were frozen and batch analyzed. 24 hour urinary collections for calcium,&#xD;
      creatinine, sulfate, citrate and sodium were analyzed at Quest Diagnostics. BMD was performed&#xD;
      at lumbar spine, total hip and femoral neck using dual-energy X-ray Absorptiometry (DXA)&#xD;
      Hologic; Bedford, Massachusetts. The least significant change (LSC) for the DXA was 0.025 at&#xD;
      the lumbar spine, 0.025 at the femoral neck and 0.015 at the radius. Two technologists, both&#xD;
      certified by the International Society for Clinical Densitometry, performed all DXA testing&#xD;
      on the participants.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2006</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double Blind Placebo Controlled Trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary-N-telopeptide</measure>
    <time_frame>Baseline,1,3,6,12 months</time_frame>
    <description>One measure of bone turnover was urinary-NTX as a second void morning urine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>P1NP (Amino-terminal Propeptide of Type I Procollagen)</measure>
    <time_frame>Baseline,1,3,6,12 months</time_frame>
    <description>One measure of bone turnover was P1NP as a morning lab draw.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Stable Bone Mineral Density (BMD) Over 12 Months at All Sites.</measure>
    <time_frame>1 year</time_frame>
    <description>BMD was performed at lumbar spine, total hip and femoral neck using dual-energy X-ray Absorptiometry (DXA) Hologic; Bedford, Massachusetts.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">83</enrollment>
  <condition>Bone Diseases, Metabolic</condition>
  <condition>Osteoporosis, Postmenopausal</condition>
  <arm_group>
    <arm_group_label>Potassium Citrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Potassium Citrate 20 meq twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>potassium citrate</intervention_name>
    <description>20 meq by mouth in capsule form twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Potassium Citrate</arm_group_label>
    <other_name>uro cit</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Postmenopausal women, more than 2 years post menopause&#xD;
&#xD;
          -  Osteopenia, defined as a T score at the lumbar spine or total hip between -1.0 and&#xD;
             -2.5&#xD;
&#xD;
          -  No history of prior fragility fracture&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Renal insufficiency&#xD;
&#xD;
          -  Use of potassium sparing diuretics&#xD;
&#xD;
          -  Use of potassium supplements&#xD;
&#xD;
          -  Hyperkalemia&#xD;
&#xD;
          -  Secondary causes of osteoporosis or metabolic bone disease&#xD;
&#xD;
          -  Delayed gastric emptying&#xD;
&#xD;
          -  esophageal compression, intestinal obstruction or stricture&#xD;
&#xD;
          -  use of anticholinergic medication&#xD;
&#xD;
          -  active urinary tract infection.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naina Sinha Gregory, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gregory NS, Kumar R, Stein EM, Alexander E, Christos P, Bockman RS, Rodman JS. POTASSIUM CITRATE DECREASES BONE RESORPTION IN POSTMENOPAUSAL WOMEN WITH OSTEOPENIA: A RANDOMIZED, DOUBLE-BLIND CLINICAL TRIAL. Endocr Pract. 2015 Dec;21(12):1380-6. doi: 10.4158/EP15738.OR. Epub 2015 Sep 24.</citation>
    <PMID>26401577</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>July 25, 2006</study_first_submitted>
  <study_first_submitted_qc>July 26, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2006</study_first_posted>
  <results_first_submitted>February 21, 2017</results_first_submitted>
  <results_first_submitted_qc>May 11, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 12, 2017</results_first_posted>
  <last_update_submitted>May 11, 2017</last_update_submitted>
  <last_update_submitted_qc>May 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>postmenopausal osteopenia</keyword>
  <keyword>treatment</keyword>
  <keyword>bone loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Bone Diseases</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Potassium Citrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Potassium Citrate</title>
          <description>Potassium Citrate 20 meq twice daily&#xD;
potassium citrate: 20 meq by mouth in capsule form twice daily</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo&#xD;
Placebo 20 meq by mouth in capsule form twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
        </group>
        <group group_id="B2">
          <title>Potassium Citrate</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
            <count group_id="B2" value="42"/>
            <count group_id="B3" value="83"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.1" spread="7.1"/>
                    <measurement group_id="B2" value="65.1" spread="5.9"/>
                    <measurement group_id="B3" value="65.8" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>New York City &amp; Surrounding Environs</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m2</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23" spread="2.5"/>
                    <measurement group_id="B2" value="24" spread="3.3"/>
                    <measurement group_id="B3" value="23" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PTH</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.8" spread="25"/>
                    <measurement group_id="B2" value="56.9" spread="33.4"/>
                    <measurement group_id="B3" value="57.2" spread="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>25-OH Vitamin D</title>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.3" spread="12.7"/>
                    <measurement group_id="B2" value="31.3" spread="13.3"/>
                    <measurement group_id="B3" value="33.3" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Urinary-N-telopeptide</title>
        <description>One measure of bone turnover was urinary-NTX as a second void morning urine.</description>
        <time_frame>Baseline,1,3,6,12 months</time_frame>
        <population>The numbers analyzed reflect the number of participants evaluable at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Potassium Citrate</title>
          </group>
        </group_list>
        <measure>
          <title>Urinary-N-telopeptide</title>
          <description>One measure of bone turnover was urinary-NTX as a second void morning urine.</description>
          <population>The numbers analyzed reflect the number of participants evaluable at each time point.</population>
          <units>nml BCE/nmol creatinine</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.2" spread="19.6"/>
                    <measurement group_id="O2" value="51.6" spread="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.5" spread="22.5"/>
                    <measurement group_id="O2" value="47" spread="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.8" spread="21.2"/>
                    <measurement group_id="O2" value="40.5" spread="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.4" spread="11.6"/>
                    <measurement group_id="O2" value="41.6" spread="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.1" spread="13.9"/>
                    <measurement group_id="O2" value="41.6" spread="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Stable Bone Mineral Density (BMD) Over 12 Months at All Sites.</title>
        <description>BMD was performed at lumbar spine, total hip and femoral neck using dual-energy X-ray Absorptiometry (DXA) Hologic; Bedford, Massachusetts.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Potassium Citrate</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Stable Bone Mineral Density (BMD) Over 12 Months at All Sites.</title>
          <description>BMD was performed at lumbar spine, total hip and femoral neck using dual-energy X-ray Absorptiometry (DXA) Hologic; Bedford, Massachusetts.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>P1NP (Amino-terminal Propeptide of Type I Procollagen)</title>
        <description>One measure of bone turnover was P1NP as a morning lab draw.</description>
        <time_frame>Baseline,1,3,6,12 months</time_frame>
        <population>The numbers analyzed reflect the number of participants evaluable at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Potassium Citrate</title>
          </group>
        </group_list>
        <measure>
          <title>P1NP (Amino-terminal Propeptide of Type I Procollagen)</title>
          <description>One measure of bone turnover was P1NP as a morning lab draw.</description>
          <population>The numbers analyzed reflect the number of participants evaluable at each time point.</population>
          <units>micrograms/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.6" spread="20.1"/>
                    <measurement group_id="O2" value="55.5" spread="23.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.9" spread="19.2"/>
                    <measurement group_id="O2" value="48.1" spread="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.7" spread="18.3"/>
                    <measurement group_id="O2" value="43.5" spread="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.0" spread="15.0"/>
                    <measurement group_id="O2" value="43.2" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.5" spread="16.5"/>
                    <measurement group_id="O2" value="42.4" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Potassium Citrate</title>
          <description>Potassium Citrate 20 meq twice daily&#xD;
potassium citrate: 20 meq by mouth in capsule form twice daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo&#xD;
potassium citrate: 20 meq by mouth in capsule form twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Symptoms</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Traumatic Ankle Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Possible dual effect of calcium citrate, which mitigated the net effect of the alkalinizing treatment. The dose of K-citrate may not be sufficient to produce a change in BMD. Duration of treatment may have been too short to see changes in BMD.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Assistant Professor of Medicine</name_or_title>
      <organization>Weill Medical College</organization>
      <phone>212-746-1670</phone>
      <email>sinhana@med.cornell.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

